RxSight, Inc. Reports Strong Q1 2025 Revenue Growth

Rxsight, Inc. ( (RXST) ) has released its Q1 earnings. Here is a breakdown of the information Rxsight, Inc. presented to its investors.

RxSight, Inc. is an ophthalmic medical device company specializing in customizable vision solutions for patients post-cataract surgery, featuring the unique Light Adjustable Lens system. In its first quarter of 2025, RxSight reported a revenue of $37.9 million, marking a 28% increase from the previous year, driven by a significant rise in sales of its Light Adjustable Lenses and Light Delivery Devices. The company achieved a gross profit of $28.3 million, up from $20.7 million in the same quarter of 2024, with a gross margin improvement to 74.8%. Despite a net loss of $8.2 million, RxSight showed a reduced adjusted net loss compared to the previous year, indicating operational improvements. Looking ahead, RxSight remains optimistic about its growth potential, backed by strong market interest and an expanding product pipeline, as it continues to lead advancements in the premium intraocular lens market.